MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,322,565
EPS
-$1.14
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
General and administrative expenses
2,634,745
1,742,315
2,302,141.5*
2,044,937
Research and development expenses
705,151
771,508
1,451,223.5*
688,465
Depreciation expense
504
555
5,671*
401
Total operating expenses
3,340,400
2,514,378
3,759,036
2,733,803
Loss from operations
-3,340,400
-2,514,378
-3,759,036*
-2,733,803
Interest and dividend income
17,835
17,838
51,162
48,098
Total other income
17,835
17,838
51,162*
48,098
Net loss and comprehensive loss
-3,322,565
-2,496,540
-3,707,874
-2,685,705
Basic EPS
-1.14
-1.04
-1.877
-1.31
Diluted EPS
-1.14
-1.04
-1.877
-1.31
Basic Average Shares
2,913,225
2,407,665
1,975,596
2,044,033
Diluted Average Shares
2,913,225
2,407,665
1,975,596
2,044,033
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest and dividend
income
$17,835
(-73.38%↓ Y/Y)
Net loss and
comprehensive loss
-$3,322,565
(9.40%↑ Y/Y)
Total other income
$17,835
(-73.38%↓ Y/Y)
Loss from operations
-$3,340,400
(10.55%↑ Y/Y)
Total operating
expenses
$3,340,400
(-10.55%↓ Y/Y)
General and
administrative expenses
$2,634,745
(-0.81%↓ Y/Y)
Research and development
expenses
$705,151
(-34.56%↓ Y/Y)
Depreciation expense
$504
(25.69%↑ Y/Y)
Buy us a coffee
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)